TY - JOUR
T1 - Central nervous system manifestations of marginal zone B-cell lymphoma
AU - Bayraktar, Soley
AU - Stefanovic, Alexandra
AU - Montague, Naomi
AU - Davis, Janet
AU - Murray, Timothy
AU - Lossos, Izidore S.
N1 - Funding Information:
Funding This work was supported by the United States Public Health Service, National Institutes of Health [grant numbers R01-CA109335, R01-CA122105], and the Dwoskin Family Foundation.
PY - 2010/10
Y1 - 2010/10
N2 - Primary or secondary central nervous system (CNS) involvement by marginal zone B-cell lymphoma (MZBCL) is rare. A retrospective analysis of patients was done with MZBCL involving the CNS, diagnosed and treated at our institution between 2004 and 2010. We identified 10 MZBCL patients with primary (six) or secondary (four) CNS involvement. Five patients presented with primary dural lymphoma and were treated with surgical resection, whole-brain radiation, or systemic chemotherapy. Only one patient had CNS relapse 5 years later. A single patient with primary intraocular lymphoma achieved clinical remission with ocular radiotherapy and systemic chemotherapy. Four patients had ocular MZBCL within 5 years of the initial diagnosis of primary ocular adnexal MZBCL and primary splenic MZBCL. There was no evidence of local recurrence in all but one who developed systemic relapse after 3 years of follow-up. Primary or secondary CNS involvement by MZBCL display indolent clinical behavior and have a generally favorable prognosis, underlining the importance of their differentiation from aggressive lymphomas that more commonly involve the CNS.
AB - Primary or secondary central nervous system (CNS) involvement by marginal zone B-cell lymphoma (MZBCL) is rare. A retrospective analysis of patients was done with MZBCL involving the CNS, diagnosed and treated at our institution between 2004 and 2010. We identified 10 MZBCL patients with primary (six) or secondary (four) CNS involvement. Five patients presented with primary dural lymphoma and were treated with surgical resection, whole-brain radiation, or systemic chemotherapy. Only one patient had CNS relapse 5 years later. A single patient with primary intraocular lymphoma achieved clinical remission with ocular radiotherapy and systemic chemotherapy. Four patients had ocular MZBCL within 5 years of the initial diagnosis of primary ocular adnexal MZBCL and primary splenic MZBCL. There was no evidence of local recurrence in all but one who developed systemic relapse after 3 years of follow-up. Primary or secondary CNS involvement by MZBCL display indolent clinical behavior and have a generally favorable prognosis, underlining the importance of their differentiation from aggressive lymphomas that more commonly involve the CNS.
KW - Marginal zone B-cell lymphoma
KW - Primary CNS lymphoma
KW - Primary dural lymphoma
KW - Primary intraocular lymphoma
UR - http://www.scopus.com/inward/record.url?scp=77956671176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956671176&partnerID=8YFLogxK
U2 - 10.1007/s00277-010-0976-3
DO - 10.1007/s00277-010-0976-3
M3 - Article
C2 - 20440502
AN - SCOPUS:77956671176
VL - 89
SP - 1003
EP - 1009
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 10
ER -